Drug Search Results
More Filters [+]

Vepoloxamer

Alternative Names: vepoloxamer, mst-188, mst188, mst 188
Latest Update: 2024-03-31
Latest Update Note: PubMed Publication

Product Description

an investigational therapy for sickle cell disease (SCD) (Sourced from: https://ashpublications.org/ashclinicalnews/news/2915/Vepoloxamer-Does-Not-Meet-Primary-Endpoint-in)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vepoloxamer

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Anemia, Sickle Cell

Phase 2: Heart Failure, Chronic|Other

Phase 1: Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Evaluation of Purified Poloxamer 188 in Subjects in Crisis (EPIC)

P3

Completed

Anemia, Sickle Cell

2017-01-16

MST-188-07

P2

Terminated

Other

2016-12-01

MST-188-10

P1

Completed

Kidney Diseases

2016-11-01

MST-188-09

P2

Terminated

Heart Failure, Chronic

2016-10-01

Recent News Events